Hiddo J L Heerspink, Lesley Inker, Niels Jongs, Sean J Barbour, Jonathan Barratt, J M Beernink, Morgan Grams, Bengt Fellstrom, Kei Fukami, William G Herrington, W Greg Miller, Peter Rossing, Joseph Vassalotti, Kerry Willis, Ron Gansevoort
{"title":"Making IMPACT (Improving Methodology for Proteinuria and Albuminuria measurement in Clinics and Trials): A Report of the 2025 Proteinuria-Albuminuria Workshop Sponsored by the National Kidney Foundation.","authors":"Hiddo J L Heerspink, Lesley Inker, Niels Jongs, Sean J Barbour, Jonathan Barratt, J M Beernink, Morgan Grams, Bengt Fellstrom, Kei Fukami, William G Herrington, W Greg Miller, Peter Rossing, Joseph Vassalotti, Kerry Willis, Ron Gansevoort","doi":"10.1053/j.ajkd.2026.10.004","DOIUrl":"https://doi.org/10.1053/j.ajkd.2026.10.004","url":null,"abstract":"<p><p>Glomerular damage is traditionally assessed by measuring urinary protein loss. While both the urinary albumin-creatinine ratio (UACR) and protein-creatinine ratio (UPCR) are used in clinical practice via 24-hour or spot urine samples, a more uniform approach to the assessment of urinary proteins and guidance when and how to assess urinary proteins would facilitate the diagnosis and monitoring of CKD. The United States National Kidney Foundation sponsored a scientific workshop to define optimal methods for the measurement of urinary proteins in April 2025. Based on existing literature, prospective studies and meta-analyses, workshop participants concluded that in general the measurement of urinary albumin is preferred over measurement of total urinary protein for several reasons. Firstly, urinary albumin assays are expected to be internationally standardized beginning in 2027, allowing optimal comparability within laboratories over time and across laboratories. Secondly, optimal pre-analytical handling of urine samples are well documented for urinary albumin unlike protein. Thirdly, urinary albumin concentration shows a moderately stronger association with clinical outcomes compared to urinary total protein, particularly in high-risk individuals. Thus, measurement of urinary albumin concentration should in general be preferred when determining the urinary excretion of proteins in future clinical practice and trials.</p>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149400936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sai Liu, Wolfgang C Winkelmayer, Maria E Montez-Rath, Tara I Chang
{"title":"Patterns of Anticoagulant Use in Older Medicare Beneficiaries with Advanced CKD and Newly Diagnosed Atrial Fibrillation.","authors":"Sai Liu, Wolfgang C Winkelmayer, Maria E Montez-Rath, Tara I Chang","doi":"10.1053/j.ajkd.2026.07.019","DOIUrl":"https://doi.org/10.1053/j.ajkd.2026.07.019","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149392448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maryam Vasaghi-Gharamaleki, Seyed Behnam Jazayeri, Abhiram Pillai, Kirsten L Johansen, Anne M Murray, Sanaz Sedaghat, Behnam Sabayan
{"title":"The Burden of Occult Cerebrovascular Disease in CKD: A Scoping Review.","authors":"Maryam Vasaghi-Gharamaleki, Seyed Behnam Jazayeri, Abhiram Pillai, Kirsten L Johansen, Anne M Murray, Sanaz Sedaghat, Behnam Sabayan","doi":"10.1053/j.ajkd.2026.07.018","DOIUrl":"https://doi.org/10.1053/j.ajkd.2026.07.018","url":null,"abstract":"<p><strong>Rationale & objective: </strong>Occult cerebrovascular diseases (OCCD) including extracranial and intracranial atherosclerotic disease (ECAD and ICAD) and cerebral small vessel disease (CSVD) are asymptomatic cerebrovascular abnormalities associated with future risk of stroke and dementia. Although chronic kidney disease (CKD) is strongly associated with adverse brain health outcomes, the breadth of evidence regarding OCCD in people with CKD has not been comprehensively characterized. This scoping review summarizes the available literature on OCCD among adults with CKD without clinically overt cerebrovascular disease.</p><p><strong>Sources of evidence: </strong>PubMed, EMBASE, Web of Science, and Scopus were searched for studies published between January 2000 and July 2025.</p><p><strong>Eligibility criteria: </strong>Peer-reviewed studies reporting the frequency or characteristics of OCCD manifestations in adults with CKD without a known history of stroke or transient ischemic attack.</p><p><strong>Charting methods: </strong>Two reviewers independently screened studies and extracted data on study characteristics, CKD definitions, neuroimaging modalities, and reported OCCD findings. Methodological quality was assessed using a modified Newcastle-Ottawa Scale.</p><p><strong>Results: </strong>Forty-six studies comprising 5,153 participants with CKD were included. Study populations varied substantially with respect to CKD stage, dialysis status, study design, and imaging methodology. Two studies evaluating ICAD reported moderate-to-severe intracranial stenosis in approximately one-quarter of participants with CKD. Across studies evaluating ECAD, the frequency of significant extracranial carotid stenosis ranged from approximately 3% in patients with non-dialysis-dependent CKD to 28% among patients receiving dialysis. Thirty-eight studies evaluated manifestations of CSVD, including cerebral microbleeds, silent cerebral infarctions, white matter hyperintensities, and enlarged perivascular spaces. Several studies suggested a greater burden of CSVD manifestations among patients with advanced CKD or dialysis dependence. Reported frequencies varied considerably across studies.</p><p><strong>Limitations: </strong>Considerable heterogeneity in study populations, CKD definitions, imaging protocols, and outcome ascertainment methods limited direct comparison across studies.</p><p><strong>Conclusions: </strong>Occult cerebrovascular abnormalities are frequently reported across diverse CKD populations, particularly among patients with advanced kidney disease. Variation in the prevalence of abnormalities may reflect differences in CKD severity, participant characteristics, neuroimaging protocols, and outcome definitions. These findings highlight the need for standardized neuroimaging approaches and prospective studies to better characterize the clinical implications of OCCD in CKD.</p>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149392449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Regina M Longley, Cecilia Katzenstein, Isabelle Band, Dinushika Mohottige, Krishna Chokshi
{"title":"Dialysis-Related Ethics Consultations Among Hospitalized Patients: Patterns and Outcomes at an Urban Academic Center.","authors":"Regina M Longley, Cecilia Katzenstein, Isabelle Band, Dinushika Mohottige, Krishna Chokshi","doi":"10.1053/j.ajkd.2026.08.010","DOIUrl":"https://doi.org/10.1053/j.ajkd.2026.08.010","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149392447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yan Ouyang, Hong Ren, Weiming Wang, Na Liu, Beiyan Bao, Hua Li, Xiaoling Xiong, Jian Li, Duolao Wang, Qinjie Weng, Chaohui Wang, Jingyuan Xie, Nan Chen
{"title":"Rituximab in IgA Nephropathy: The RITA Multicenter Randomized Trial.","authors":"Yan Ouyang, Hong Ren, Weiming Wang, Na Liu, Beiyan Bao, Hua Li, Xiaoling Xiong, Jian Li, Duolao Wang, Qinjie Weng, Chaohui Wang, Jingyuan Xie, Nan Chen","doi":"10.1053/j.ajkd.2026.07.017","DOIUrl":"https://doi.org/10.1053/j.ajkd.2026.07.017","url":null,"abstract":"<p><strong>Rationale & objective: </strong>B-cell dysregulation contributes to IgA nephropathy (IgAN). Rituximab (RTX) targets CD20-positive B cells, but its efficacy in adults with IgAN receiving stable renin-angiotensin system inhibitor (RASI) therapy remains uncertain. This study sought to evaluate the efficacy and safety of RTX combined with RASI therapy compared with RASI therapy alone.</p><p><strong>Study design: </strong>Multicenter, randomized, controlled trial.</p><p><strong>Setting & participants: </strong>Chinese adults with biopsy-proven IgAN across 10 centers, with 24-hour urine total protein (UTP) >1 g/day despite ≥3 months RASI therapy, and blood pressure <130/80 mmHg.</p><p><strong>Interventions: </strong>RTX plus RASI versus RASI alone for 12 months OUTCOMES: Primary: 24-hour UTP change at month 12. Secondary continuous: changes in 24-hour UTP at month 6 and in eGFR and serum Gd-IgA1 at month 12. Secondary categorical: ≥50% reduction in 24-hour UTP at months 6 and 12, ≥50% eGFR decline or doubling of serum creatinine, and ESKD.</p><p><strong>Safety: </strong>adverse events, serious adverse events, and infections. Exploratory analyses examined outcomes through month 24.</p><p><strong>Results: </strong>Among the 106 participants randomized (53 per group), 24-hour UTP change at 12 months was similar between groups (adjusted GMR, 1.05; 95% CI, 0.80-1.36). Median change of 24-hour UTP was -0.21 g/day for RTX and -0.26 g/day for RASI. No statistically significant differences were observed in eGFR (adjusted mean difference, 3.80 mL/min/1.73 m<sup>2</sup>; 95% CI, -0.47 to 8.06), Gd-IgA1 (adjusted GMR, 1.04; 95% CI, 0.87-1.24), or the proportion achieving a ≥50% reduction in 24-hour UTP (15.1% vs 20.8%). Adverse events occurred at similar rates between two groups; no events of ≥50% eGFR decline, doubling of serum creatinine, or ESKD occurred during the 12-month treatment period. These findings were consistent with analyses that included outcome data through month 24.</p><p><strong>Limitations: </strong>The follow-up period was relatively short, and only Asian patients were enrolled.</p><p><strong>Conclusions: </strong>No additional reduction in proteinuria or preservation of kidney function was observed with the addition of RTX to optimized RASI-based therapy in patients with IgAN.</p><p><strong>Funding: </strong>Grants from government (National Key Research and Development Program, Major International [Regional] Joint Research Program of China, National Natural Science Foundation of China, National Facility for Translational Medicine [Shanghai], Shanghai 'Rising Stars of Medical Talent' Youth Development Program), academic (Shanghai Shenkang Hospital Development Center), and non-profit (International Society of Nephrology) sources.</p>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149369820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abraham J Matar, Clark Kensinger, Alvin G Thomas, Kenneth Chavin, Raja Kandaswamy
{"title":"Therapeutic Living Kidney Donation for Symptomatic Nutcracker Syndrome: A Multicenter Experience Using Kidney Paired Exchange.","authors":"Abraham J Matar, Clark Kensinger, Alvin G Thomas, Kenneth Chavin, Raja Kandaswamy","doi":"10.1053/j.ajkd.2026.06.039","DOIUrl":"https://doi.org/10.1053/j.ajkd.2026.06.039","url":null,"abstract":"<p><p>Therapeutic living kidney donation (TLKD), in which a nephrectomy is performed as definitive treatment for a donor condition, remains uncommon. This multicenter study reports outcomes of seven patients from three centers with symptomatic nutcracker syndrome (NCS) who underwent TLKD through kidney paired exchange between 2022-2024. Among the seven donors, the majority were female (n = 6). Median age was 38 y (range: 23-55 y), and median BMI was 22.9 (range: 19.0-32.6). Nephrectomies were performed via laparoscopic (n = 2), laparoscopic hand-assisted (n = 4), or open (n = 1) technique. All kidneys were transplanted successfully through national paired kidney exchange. Donor creatinine levels increased from a mean of 0.71 mg/dL preoperatively to 1.08 mg/dL at six months. All donors reported symptom relief, with no perioperative complications. Recipient outcomes showed stable renal function, with mean creatinine of 1.1 mg/dL at 6 months and 1.2 mg/dL at 1 year. TLKD offers symptom resolution for appropriately selected donors and access to transplantation for recipients. Further longitudinal data will clarify patient selection and long-term outcomes, but these data suggest TLKD in refractory NCS is feasible.</p>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bénédicte Piron, Jérôme Han Yee Yu, Hélène Caillon, Virginie Pascal, Benoit Tessoulin, Cyrille Touzeau, Yannick Le Bris, Karine Renaudin, Nicolas Blin, Simon Ville
{"title":"B-Cell Maturation Antigen T-Cell Engager Therapy in a Patient With Refractory Plasma Cell Clonal Cryoglobulinemia Unmasked by RNA-Based Immunoglobulin Sequencing.","authors":"Bénédicte Piron, Jérôme Han Yee Yu, Hélène Caillon, Virginie Pascal, Benoit Tessoulin, Cyrille Touzeau, Yannick Le Bris, Karine Renaudin, Nicolas Blin, Simon Ville","doi":"10.1053/j.ajkd.2026.06.038","DOIUrl":"https://doi.org/10.1053/j.ajkd.2026.06.038","url":null,"abstract":"<p><p>Treatment of type I cryoglobulinemic glomerulonephritis depends on identifying the monoclonal clone responsible for cryoglobulin secretion. We report the case of a woman in whom the culprit clone proved exceptionally difficult to detect, making treatment guidance highly uncertain. Using the RACE RepSeq technique combined with innovative bone marrow cell sorting, and later through direct visualization within the kidney, we identified a likely plasma cell clone responsible for the cryoglobulin. Despite targeted interventions, the disease remained refractory to conventional therapies, teclistamab, a bispecific T-cell-engaging antibody redirecting T cells against plasma cells, achieved efficacy. Finally, residual disease monitoring was possible through a novel targeted mass spectrometry approach (MALDI-TOF MS), sensitive enough to visualize the cryoglobulin M-protein. This case highlights the challenges of detecting elusive monoclonal clones in many monoclonal gammopathies of renal significance, illustrates the potential of advanced diagnostic tools, and underscores the promise of T-cell-redirecting therapies in refractory cryoglobulinemic glomerulonephritis.</p>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149316988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ishfaq Rashid, Hiddo J L Heerspink, Lesley A Inker
{"title":"An Albuminuria Guided Approach to Risk Stratification and Therapeutic Decision-Making in CKD.","authors":"Ishfaq Rashid, Hiddo J L Heerspink, Lesley A Inker","doi":"10.1053/j.ajkd.2026.06.033","DOIUrl":"https://doi.org/10.1053/j.ajkd.2026.06.033","url":null,"abstract":"<p><p>Chronic kidney disease (CKD) is a global public health challenge, yet therapeutic evaluation and regulatory acceptance are constrained by reliance on late clinical endpoints such as kidney failure. Albuminuria, assessed as urine albumin-to-creatinine ratio (UACR) reflects glomerular and systemic vascular injury and responds rapidly to treatment. Epidemiologic evidence demonstrates a continuous, graded association between both baseline and changes in UACR and subsequent risk for kidney failure, cardiovascular events, and mortality. Trial level analyses demonstrate that treatment effects on change in UACR is also associated with long-term treatment benefit on CKD progression across drug classes and disease populations. Meta-analysis indicates that a treatment benefit of ≥30% decline in UACR is associated with approximately a 20% treatment benefit on CKD progression, supporting its use as a clinically meaningful surrogate endpoint. Residual albuminuria during treatment identifies patients at persistently high risk and provides a rationale for therapy intensification. Recent studies demonstrate that combination therapies can achieve substantial additional reductions in UACR, in selected settings exceeding 50%. This review synthesizes biological, epidemiologic, and clinical trial evidence supporting albuminuria-guided risk stratification and a treat-to-target approach using serial UACR monitoring to personalize CKD care, while improving clinician understanding of albuminuria changes as markers of therapeutic response.</p>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149316986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lihong Bu, Lisa E Vaughan, Samar M Said, Yi Zhu, Chuan Chen, Mohammed Abdalla, Alessia Buglioni, Pingchuan Zhang, Loren Herrera Hernandez, Sanjeev Sethi, Christopher P Larsen, Nelson Leung, Samih H Nasr
{"title":"Proliferative Glomerulonephritis With Monotypic Immunoglobulin Deposits of IgG1 Subclass: A Case Series.","authors":"Lihong Bu, Lisa E Vaughan, Samar M Said, Yi Zhu, Chuan Chen, Mohammed Abdalla, Alessia Buglioni, Pingchuan Zhang, Loren Herrera Hernandez, Sanjeev Sethi, Christopher P Larsen, Nelson Leung, Samih H Nasr","doi":"10.1053/j.ajkd.2026.07.016","DOIUrl":"https://doi.org/10.1053/j.ajkd.2026.07.016","url":null,"abstract":"<p><strong>Rationale & objective: </strong>Most cases of proliferative glomerulonephritis with monotypic immunoglobulin deposits (PGNMID) are associated with IgG3. The characteristics of IgG1 deposits within PGNMID have not been well defined and are the focus of this study.</p><p><strong>Study design: </strong>Retrospective case series.</p><p><strong>Setting & participants: </strong>Forty-six PGNMID cases with granular monotypic IgG1 deposits (PGNMID-IgG1) identified in nephropathology archives.</p><p><strong>Findings: </strong>57% of cases were male and 78% had hematuria. The median age was 57 years, the median proteinuria level was 4.8 g/day, and the median eGFR level was 52 mL/min/1.73 m<sup>2</sup>. Hypocomplementemia was uncommon (12%). Kidney biopsy revealed MPGN (54%) or mesangial proliferative GN (33%), with membranous features in nearly half (43%). A nephropathic clone or monoclonal Ig (mIg) was detected in 19 of 42 patients with PGNMID-IgG1 who underwent evaluation, including 10 with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). Among patients >50 years, the detection rate was 72% (18/25) vs. 6% (1/17) among younger patients. SPEP/SIF detected the nephropathic mIg in 13 of 40, and bone marrow biopsy done in 25 detected clonal B-cells in eight and clonal plasma cells in two patients. Follow-up (median 27 months) was available for 37 patients. Ten (83%) of 12 patients with an identifiable clone or mIg responded to clone-targeted (anti-plasma or B- cell) therapy, whereas 4 of 8 patients without an identifiable clone or mIg responded to anti-plasma cell therapy. At 60 months, the overall cumulative incidence of kidney failure requiring dialysis or death was 31.1% (7.9% to 48.5%). Four patients underwent kidney transplantation and three with transplant biopsies exhibited recurrent disease.</p><p><strong>Limitations: </strong>Retrospective, single-center study, non-standardized hematologic workup and management.</p><p><strong>Conclusions: </strong>Nearly 75% of PGNMID-IgG1 cases >50 years of age have a clonal population detected and nearly a quarter have CLL/SLL. Response to anti-B-cell therapy may be greater in those with an identifiable clone or mIg. These data may inform treatment strategies for people with PGNMID-IgG1.</p>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Innovative Management of Non-HLA Antibody and NK Cell-Mediated Rejection After Kidney Transplantation With Imlifidase: A Case Report.","authors":"Florent Von Tokarski, Marion Rabant, Valentin Goutaudier, Dany Anglicheau, Lionel Couzi, Maryvonnick Carmagnat, Emilie Lebraud, Anaïs Certain, Jessy Dagobert, Ramia Benhamou, Eva Languille-Llitjos, Alexandre Loupy, Jean-Luc Taupin, Florence Runyo, Alexandre Hertig, Arwa Jalal Eddine","doi":"10.1053/j.ajkd.2026.06.035","DOIUrl":"https://doi.org/10.1053/j.ajkd.2026.06.035","url":null,"abstract":"<p><p>A highly sensitized patient received a kidney transplant (KT) following imlifidase induction: we report an innovative diagnostic and therapeutic strategy for rejection management. On day 20 post-KT, the patient developed acute kidney injury, with donor-derived cell-free DNA (dd-cfDNA) increasing to 1.93%. Histology revealed isolated glomerulitis (g1) with C4d(2+) deposits along peritubular capillaries. Steroids and plasma exchanges were administered for suspected antibody-mediated rejection (AMR), despite no rebound of donor-specific anti-HLA antibodies (DSAs). Non-HLA anti-endothelial cell antibodies were positive, confirming AMR according to Banff 2022. Transcriptomic analysis showed overexpression of complement pathway-associated transcripts. C5 inhibition failed as serum creatinine further increased along with dd-cfDNA (3.96%). A second biopsy confirmed active AMR with increased expression of NK-related transcripts, leading to anti-CD38 treatment (daratumumab). At 6 months post-KT, the condition was controlled with stable creatinine at 20.4 μg/mL, dd-cfDNA decreased to 0.1%, microvascular inflammation resolved, non-HLA anti-endothelial cell antibodies became undetectable, still without HLA DSA rebound. Daratumumab is ongoing. Integrating dd-cfDNA, transcriptomic biopsy analysis, and non-HLA antibody assessment may optimize the management of highly sensitized KT recipients following imlifidase induction. However, long-term efficacy remains to be confirmed.</p>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149316994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}